The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer

被引:14
作者
Cude, KJ [1 ]
Montgomery, JS [1 ]
Price, DK [1 ]
Dixon, SC [1 ]
Kincaid, RL [1 ]
Kovacs, KF [1 ]
Venzon, DJ [1 ]
Liewehr, DJ [1 ]
Johnson, ME [1 ]
Reed, E [1 ]
Figg, WD [1 ]
机构
[1] NCI, Med Branch, Dept Clin Sci, NIH, Bethesda, MD 20892 USA
关键词
prostate cancer; androgen receptor; CAG trinucleotide repeat;
D O I
10.1159/000048412
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The androgen receptor plays a major role in the development and function of normal and malignant prostate cells. Due to the relationship of the androgen receptor and prostatic growth, it has been proposed that polymorphisms within the androgen receptor may play a role in an individual's susceptibility to developing prostate cancer. An inverse relationship has been established between a highly polymorphic trinucleotide repeat located in the first exon of the androgen receptor and the transactivaton function of the receptor. Serum samples were collected from 131 patients with histologically confirmed adenocarcinoma of the prostate, DNA was isolated, and the polymorphic CAG repeat was amplified by PCR and sequenced. The CAG repeat lengths were then compared with age at diagnosis, age at time of study, baseline log(10) PSA, Gleason score, time from diagnosis to initiation of hormonal therapy, time to progression after androgen ablation, and overall survival time. No correlation was found between CAG length and time to progression or overall survival time, but a significant correlation was found between Gleason score and CAG length suggesting that shorter CAG lengths may predict a higher histological grade of prostate cancer. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:16 / 23
页数:8
相关论文
共 27 条
  • [1] A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: Toxicity and response
    Bowden, CJ
    Figg, WD
    Dawson, NA
    Sartor, O
    Bitton, RJ
    Weinberger, MS
    Headlee, D
    Reed, E
    Myers, CE
    Cooper, MR
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 39 (1-2) : 1 - 8
  • [2] CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk
    Bratt, O
    Borg, Å
    Kristoffersson, U
    Lundgren, R
    Zhang, QX
    Olsson, H
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (04) : 672 - 676
  • [3] THE LENGTH AND LOCATION OF CAG TRINUCLEOTIDE REPEATS IN THE ANDROGEN RECEPTOR N-TERMINAL DOMAIN AFFECT TRANSACTIVATION FUNCTION
    CHAMBERLAIN, NL
    DRIVER, ED
    MIESFELD, RL
    [J]. NUCLEIC ACIDS RESEARCH, 1994, 22 (15) : 3181 - 3186
  • [4] PROSTATE-CANCER AND THE ANDROGEN RECEPTOR
    COETZEE, GA
    ROSS, RK
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) : 872 - 873
  • [5] Dawson N, 1998, CLIN CANCER RES, V4, P37
  • [6] Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer
    Dawson, NA
    Figg, WD
    Cooper, MR
    Sartor, O
    Bergan, RC
    Senderowicz, AM
    Steinberg, SM
    Tompkins, A
    Weinberger, B
    Sausville, EA
    Reed, E
    Myers, CE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1470 - 1477
  • [7] DAWSON NA, 1995, CANCER, V76, P453, DOI 10.1002/1097-0142(19950801)76:3<453::AID-CNCR2820760316>3.0.CO
  • [8] 2-E
  • [9] Methods for extracting and amplifying genomic DNA isolated from frozen serum
    Dixon, SC
    Horti, J
    Guo, Y
    Reed, E
    Figg, WD
    [J]. NATURE BIOTECHNOLOGY, 1998, 16 (01) : 91 - 94
  • [10] Edwards SM, 1999, INT J CANCER, V84, P458, DOI 10.1002/(SICI)1097-0215(19991022)84:5<458::AID-IJC2>3.0.CO